Analysts think CLRB stock price could increase by 294%
Jun 14, 2024, 6:28 AM
-13.82%
What does CLRB do
Cellectar Biosciences, Inc., based in Florham Park, New Jersey, develops phospholipid drug conjugates (PDCs) for cancer treatment and imaging, and went public in 2005. The company's pipeline includes iopofosine for targeted cancer therapy, currently under evaluation in Phase 2 and Phase 1 clinical studies for multiple myeloma and pediatric cancers respectively.
6 analysts think CLRB stock price will increase by 294.06%. The current median analyst target is $13.26 compared to a current stock price of $3.37. The lowest analysts target is $7.07 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
